AUA 2023: Focus on Bladder Cancer
AUA 2023: Focus on Bladder Cancer
Advertisement
Peter Clark, MDAUA 2023: Focus on Bladder Cancer | August 3, 2023
The relevant updates to the guideline for upper tract urothelial carcinoma are provided by Dr. Peter Clark.
View More
Zachary BessetteAUA 2023: Focus on Bladder Cancer | April 29, 2023
There is significant inter-site variation in recurrence of NMIBC after TRUBT in the RESECT study, according to new research.
Zachary BessetteAUA 2023: Focus on Bladder Cancer | May 30, 2023
During an afternoon plenary session, Dr. Jonathan Coleman presented the updates to the AUA guideline for UTUC.
Emily MenendezAUA 2023: Focus on Bladder Cancer | April 28, 2023
Study results indicate an alternative strategy to radical cystectomy for comprehensive bladder-preserving therapy for MIBC.
Zachary BessetteAUA 2023: Focus on Bladder Cancer | April 28, 2023
IMvigor210 and IMvigor211 shed light on the association between irAEs and outcomes after receiving atezolizumab for aUC.
Zachary BessetteAUA 2023: Focus on Bladder Cancer | April 28, 2023
Long-term exploratory analyses of subgroups defined by response to first-line chemotherapy in the JAVELIN Bladder 100 trial.
Zachary BessetteAUA 2023: Focus on Bladder Cancer | March 11, 2024
A recent study correlated cell-free tumor DNA sequencing with response to neoadjuvant chemotherapy in patients with N+ MIBC.
Zachary BessetteAUA 2023: Focus on Bladder Cancer | April 28, 2023
A newly developed model for prediction of 90-day mortality after radical cystectomy has outperformed available nomograms.
Emily MenendezAUA 2023: Focus on Bladder Cancer | April 28, 2023
Patients with high-risk NMIBC who underwent TURBT from November 1993 to April 2019 were retrospectively evaluated.
Emily MenendezAUA 2023: Focus on Bladder Cancer | June 27, 2023
The AUA has released their 2023 clinical practice guideline for the diagnosis and treatment of nonmetastatic UTUC.
Emily MenendezAUA 2023: Focus on Bladder Cancer | April 28, 2023
A study analyzed effect of time to progression on OS in a cohort of patients with HR-NMIBC treated with intravesical BCG.
Emily MenendezAUA 2023: Focus on Bladder Cancer | May 4, 2023
TAR-200 consists of a small silicone delivery system that provides sustained, local release of gemcitabine to the bladder.
Advertisement
Advertisement
Advertisement